Extraordinary high rate of HTLV type II seropositivity in intravenous drug abusers in south Vietnam.

Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Extraordinary high rate of HTLV type II seropositivity in intravenous drug abusers in south Vietnam.

AIDS Res Hum Retroviruses. 1995 May;11(5):637-45. Unique Identifier : AIDSLINE MED/96093899
Fukushima Y; Takahashi H; Hall WW; Nakasone T; Nakata S; Song P; Dinh Duc D; Hien B; Nguyen XQ; Ngoc Trinh T; et al; Laboratory of Immunology, AIDS Research Center, National; Institute of Health, Tokyo, Japan.

Abstract: Serum specimens (n = 1899) were assayed for infections with HTLV-I, HTLV-II, and HIV-1 in seven classified groups of normal healthy controls, children, pregnant women, prostitutes, intravenous drug abusers, patients under going hemodialysis, and hemophiliacs in South and North Vietnam. Surprisingly, 125 of 954 samples from South Vietnam exhibited seropositivity for HTLV-II and 119 of these belonged to the group of IVDAs (n = 200). The remaining six positives were a healthy control, a prostitute, two children, and two patients under going hemodialysis. Two IVDAs who were seropositive for HTLV-I and 10 of 15 seropositives for HIV-1 were also positive for HTLV-II in this population. In contrast, no seropositives to any of the viruses were detected in the North Vietnamese samples (0 of 945). The HTLV-II-seropositive IVDAs exhibited increased seropositivity with age compared with HIV-1 seropositivity in the population, and there was no statistical relation between seropositivity for HTLV-II and HIV-1. The HTLV-IIs in South Vietnam IVDAs appeared, by subtype-specific peptide ELISA, to be a mixture of both subtypes a and b, with subtype a predominant. It seems possible that HTLV-II may have been introduced into this population from IVDAs from the United States during the Vietnam conflict, but in a period prior to, or early in, the introduction of HIV-1 to IVDAs.

Keywords: Adult Amino Acid Sequence Child Female Human HIV Seropositivity/BLOOD/VIROLOGY HIV-1/ISOLATION & PURIF HTLV-I/ISOLATION & PURIF HTLV-II/CLASSIFICATION/ISOLATION & PURIF HTLV-II Infections/*COMPLICATIONS/EPIDEMIOLOGY/VIROLOGY Male Molecular Sequence Data Pregnancy Seroepidemiologic Methods Substance Abuse, Intravenous/*COMPLICATIONS/VIROLOGY Support, Non-U.S. Gov't Vietnam/EPIDEMIOLOGY JOURNAL ARTICLE
960228
M9621029

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .